Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Wojciech Jurczak"'
Autor:
Frederic Peyrade, Graham P. Collins, Yihua Lee, Jutta K. Neuenburg, Michael Wang, Robert T. Chen, Geoffrey Chong, Karl Eckert, Constantine S. Tam, Radhakrishnan Ramchandren, Lionel Karlin, Ka Lung Wu, Mark Bishton, Paul Eliadis, Wojciech Jurczak
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-8 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administer
Autor:
Richard R. Furman, Lin Tao, Nataliya Kuptsova-Clarkson, Jennifer R. Brown, Wojciech Jurczak, Peter Hillmen, Javid Moslehi, Clare Sun, Paolo Ghia, John M. Pagel, John C. Byrd, Jeff P. Sharman, Priti Patel, Deborah M. Stephens, Alessandra Ferrajoli
Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is a second-generation BTK inhibitor with greater BTK se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0675404d31efe952898ebb286a11f787
https://ruj.uj.edu.pl/xmlui/handle/item/290099
https://ruj.uj.edu.pl/xmlui/handle/item/290099
Autor:
Marek Dudziński, Monika Długosz-Danecka, Małgorzata Wojciechowska, Michal Osowiecki, Elżbieta Iskierka-Jażdżewska, Weronika Piszczek, Jan Maciej Zaucha, Agnieszka Szymczyk, Edyta Subocz, Joanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Beata Kumiega, Krzysztof Giannopoulos, Ryszard Wichary, Marek Hus, Bartosz Pula, Wojciech Jurczak, Tadeusz Robak, Bożena Katarzyna Budziszewska, Janusz Hałka, Wanda Knopinska-Posluszny, Krzysztof Jamroziak, Agnieszka Szeremet, Andrzej Pluta, Daria Zawirska, Paweł Steckiewicz, Jadwiga Hołojda, Ewa Lech-Marańda
Publikováno v:
Anticancer Research. 40:4059-4066
Background/aim To study the long-term clinical efficacy and tolerability of ibrutinib monotherapy in real-world relapsed and refractory chronic lymphocytic leukemia (RR-CLL) patients outside clinical trials. Patients and methods Clinical data of 171
Autor:
Paula Marlton, Judith Trotman, Wojciech Jurczak, Gavin Cull, Tycel Phillips, Meletios A. Dimopoulos, David Gottlieb, Chenmu Du, Alessandra Tedeschi, Aileen Cohen, Stephen Opat, Roger G. Owen, Constantine S. Tam, Shirley D'Sa, Jianyong Li, Ramón García-Sanz, Wei Xu, Jane Huang, Andrew W. Roberts, Hongjie Zhu, Jun Zhu, Yuqin Song, Meng Ji, Lei Zhou, Javier Munoz, William Novotny, Wai Y. Chan, Lugui Qiu, Haiyi Guo
Publikováno v:
Blood advances. 6(4)
Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor evaluated in multiple B-cell malignancy studies. We constructed a pooled safety analysis to better understand zanubrutinib-associated treatment-emergent adverse events (TEAEs) and ide
Autor:
Aruna Mehra, L. Mongay Soler, Árpád Szomor, Muhit Ozcan, Qingyuan Zhang, Eduardo Yanez, Barrett H. Childs, Jie Jin, P. L. Zinzani, Rinat Galiulin, Florian Hiemeyer, Klaus Geissler, Igor Bondarenko, Ross I. Baker, Toshiki Uchida, Kamal Bouabdallah, Wojciech Jurczak, Anjun Cao, Jifeng Feng, Wei Li, Fangfang Lv, Aryan Hamed, M. Matasar, T. Lin, Mihaela Lazaroiu, Güray Saydam, Katya Sapunarova, Yuankai Shi, Ming-Chung Wang, Marcelo Capra
Publikováno v:
Hematological Oncology. 39
Autor:
S. Stilgenbauer, José A. García-Marco, Stéphane Leprêtre, John F. Seymour, Peter Hillmen, Arnon P. Kater, Mustafa Nuri Yenerel, Árpád Illés, Richard R. Furman, Tadeusz Robak, Anthony R. Mato, Paolo Ghia, Kara Higgins, John C. Byrd, Sophia Sohoni, Susan O'Brien, Asher Chanan-Khan, Neil E. Kay, Priti Patel, Wojciech Jurczak, Javier Pinilla-Ibarz
Publikováno v:
Hematological Oncology. 39
Publikováno v:
Hematological Oncology. 39
Autor:
Frederic Peyrade, Geoffrey Chong, Michael Wang, Lionel Karlin, Jutta K. Neuenburg, Ka Lung Wu, Mark Bishton, Wojciech Jurczak, Robert T. Chen, Edith Szafer-Glusman, Paul Eliadis, Constantine S. Tam, Graham P. Collins, Yihua Lee, Radhakrishnan Ramchandren, Karl Eckert
Publikováno v:
Blood. 136:39-41
Background : Ibrutinib (ibr) is a once-daily Bruton's tyrosine kinase (BTK) inhibitor approved in the US for patients (pts) with mantle cell lymphoma (MCL) who have received ≥1 prior therapy. Venetoclax (ven) is a BCL-2 inhibitor approved for pts w
Autor:
Ian W. Flinn, John G. Gribben, Ryan Jacobs, Monika Długosz-Danecka, John M. Burke, Tomasz Wróbel, Michael S. Weiss, Danielle M. Brander, Jeff P. Sharman, Peter Sportelli, Douglas F. Beach, Krzysztof Giannopoulos, Hari P. Miskin, Suman Kambhampati, Kathryn S. Kolibaba, Sebastian Grosicki, Nilanjan Ghosh, John M. Pagel, Jerome H. Goldschmidt, Tanya Siddiqi, Alexey V. Danilov, Javier Pinilla Ibarz, Jennifer L. Cultrera, Syed F. Zafar, Wojciech Jurczak, Owen A. O'Connor, Scott F. Huntington
Publikováno v:
Blood. 136:37-39
Background: Umbralisib is an oral, once-daily, novel, dual inhibitor of phosphatidylinositol-3-kinase-delta (PI3Kδ) and casein kinase-1ε (CK1ε) that exhibits improved selectivity for the delta isoform of PI3K. Ublituximab is a novel anti-CD20 mono
Autor:
Nataliya Kuptsova-Clarkson, Jeff P. Sharman, Peter Hillmen, Clare Sun, Marshall Baek, Deborah M. Stephens, Tamara Lezhava, Paolo Ghia, John M. Pagel, Alessandra Ferrajoli, Priti Patel, Javid Moslehi, Wojciech Jurczak, Richard R. Furman, Jennifer R. Brown, John C. Byrd
Publikováno v:
Blood. 136:52-54
Background: Bruton tyrosine kinase (BTK) inhibitors are effective treatments for B-cell malignancies, but an increased incidence of cardiovascular (CV) toxicities has been observed with ibrutinib. Acalabrutinib (acala) is a next-generation, potent, h